Weekly Investment Analysts’ Ratings Changes for Mirum Pharmaceuticals (MIRM)

Mirum Pharmaceuticals (NASDAQ: MIRM) has recently received a number of price target changes and ratings updates:

• 10/22/2026 – Mirum Pharmaceuticals was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 10/21/2026 – Mirum Pharmaceuticals had its price target raised by TD Cowen from $140.00 to $145.00. They now have a “buy” rating on the stock.
• 10/14/2026 – Mirum Pharmaceuticals had its price target raised by Stifel Nicolaus from $136.00 to $156.00. They now have a “buy” rating on the stock.
• 10/13/2026 – Mirum Pharmaceuticals had its “outperform” rating reaffirmed by Evercore. They now have a $146.00 price target on the stock.
• 10/12/2026 – Mirum Pharmaceuticals had its price target raised by Morgan Stanley from $137.00 to $152.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – Mirum Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
• 10/12/2026 – Mirum Pharmaceuticals had its price target raised by Citigroup from $160.00 to $184.00. They now have a “buy” rating on the stock.
• 10/12/2026 – Mirum Pharmaceuticals had its price target raised by HC Wainwright from $195.00 to $200.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Mirum Pharmaceuticals had its price target raised by Royal Bank Of Canada from $135.00 to $155.00. They now have an “outperform” rating on the stock.
• 9/29/2026 – Mirum Pharmaceuticals had its price target raised by Robert W. Baird from $123.00 to $130.00. They now have an “outperform” rating on the stock.
• 9/28/2026 – Mirum Pharmaceuticals was given a new $144.00 price target by Morgan Stanley.
• 9/28/2026 – Mirum Pharmaceuticals had its “buy” rating reaffirmed by Citigroup. They now have a $160.00 price target on the stock, up from $145.00.
• 9/28/2026 – Mirum Pharmaceuticals had its price target raised by HC Wainwright from $140.00 to $195.00. They now have a “buy” rating on the stock.
• 9/6/2026 – Mirum Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/29/2026 – Mirum Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/27/2026 – Mirum Pharmaceuticals was given a new $137.00 price target by UBS Group.
• 8/27/2026 – Mirum Pharmaceuticals had its “market outperform” rating reaffirmed by Citigroup.
• 8/27/2026 – Mirum Pharmaceuticals had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $137.00 price target on the stock.

Insider Transactions at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total value of $2,960,400.00. Following the transaction, the chief executive officer directly owned 194,440 shares of the company’s stock, valued at $19,187,339.20. The trade was a 13.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the sale, the chief financial officer owned 36,355 shares in the company, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 98,499 shares of company stock valued at $9,797,834. Corporate insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.